Published in Urology on October 19, 2013
Editorial comment. Urology (2013) 1.08
Serum markers in prostate cancer detection. Curr Opin Urol (2015) 0.80
Reply: To PMID 24149108. Urology (2013) 0.75
Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience. World J Urol (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2011) 9.50
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38
Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst (1995) 1.96
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology (2006) 1.51
Screening for prostate cancer. CA Cancer J Clin (2009) 1.48
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol (2005) 1.42
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology (2005) 1.16
Introducing the 2010 American Cancer Society prostate cancer screening guideline. CA Cancer J Clin (2010) 0.99
Measuring mortality reductions in cancer screening trials. Epidemiol Rev (2011) 0.91
Predicting prostate cancer many years before diagnosis: how and why? World J Urol (2011) 0.89
We need a better marker for prostate cancer. How about renaming PSA? Urology (2011) 0.84
Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc (2013) 3.40
The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol (2010) 3.08
Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol (2008) 2.97
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29
Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer (2013) 2.21
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest (2009) 2.16
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Temporal trends, practice patterns, and treatment outcomes for infected upper urinary tract stones in the United States. Eur Urol (2012) 2.16
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int (2013) 2.12
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol (2011) 2.11
Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol (2014) 2.08
A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc (2002) 2.04
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc (2009) 1.98
Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol (2009) 1.92
Delays in diagnosis and bladder cancer mortality. Cancer (2010) 1.92
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol (2008) 1.73
Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol (2011) 1.69
Prediction of treatment outcomes after global endometrial ablation. Obstet Gynecol (2009) 1.67
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol (2012) 1.58
Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol (2011) 1.58
The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology (2010) 1.54
Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53
Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol (2012) 1.53
Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care. Med Care (2014) 1.50
Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49
A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. Res Rep Urol (2012) 1.48
20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int (2012) 1.47
Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study. Mayo Clin Proc (2012) 1.46
Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy? Urology (2011) 1.45
Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. Urology (2012) 1.44
Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology (2010) 1.42
Alpha-blocker use is associated with decreased risk of sexual dysfunction. Urology (2009) 1.42
Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol (2013) 1.41
Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. BJU Int (2011) 1.41
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol (2007) 1.39
Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc (2013) 1.38
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol (2005) 1.38
Three-dimensional ultrasound bladder characteristics and their association with prostate size and lower urinary tract dysfunction among men in the community. Urology (2009) 1.37
A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol (2005) 1.37
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate (2013) 1.36
Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care (2007) 1.32
Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res (2007) 1.27
Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol (2008) 1.26
Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy. Transfusion (2014) 1.25
Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) (2013) 1.25
Dropout in a longitudinal, cohort study of urologic disease in community men. BMC Med Res Methodol (2006) 1.24
Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery (2003) 1.24
Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol (2005) 1.23
Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol (2006) 1.22
Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol (2013) 1.21
Transoral resection of tonsillar squamous cell carcinoma. Laryngoscope (2009) 1.20
Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol (2006) 1.19
Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol (2010) 1.18
Polymorphisms in mitochondrial genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.17
Diabetes and sexual dysfunction: results from the Olmsted County study of urinary symptoms and health status among men. J Urol (2007) 1.17
Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res (2008) 1.17